Q-omics provides the consensus-scored PARAL1 profile across patient tissues and cancer cell-line models. PARAL1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PARAL1 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, PARAL1 RNA expression shows 8,955 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight SKCM, LUAD, and KIRP as cancer lineages where PARAL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARAL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARAL1 survival associations across molecular data types. PARAL1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARAL1 RNA expression–survival associations across cancer types. High PARAL1 expression shows unfavorable associations in BLCA, KIRC, ACC and UVM, but favorable associations in SKCM and ESCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PARAL1 RNA expression.
This table summarizes PARAL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PARAL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARAL1 shows lower tumor expression in LUAD, LUSC and BRCA and higher tumor expression in THCA, LIHC and CHOL. The LUAD box plot shows higher PARAL1 RNA expression in normal versus tumor tissue (log2 FC = −3.413, t-test p < 0.001).
This table shows molecular features associated with PARAL1 in patient tissues and cancer cell lines. In patient samples, PARAL1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
